In early 2011, GlycoSan was acquired by BioTime - itself a a currently SBIR-involved firm. Glycosan BioSystems, Inc. produces pharmaceutical-grade hydrogels for 3D cell culture, stem cell culture, tissue engineering scaffold, and cell therapy applications. It offers hyaluronan based products, such as Extracel and HyStem-C for stem cell researchers as a starting point for optimization of a cell's microenvironment; Extracel-HP and HyStem-HP for applications requiring slow release of growth factors in a cell's microenvironment; Extracel-X for growing tumor xenografts in mice; Extracel-SS and HyStem-CSS that allows recovery of encapsulated cells in 3-D cultures; and HyStem for applications requiring attachment factor optimization. The company also provides PEG based products polyethylene glycol diacrylate-based (PEGDA) hydrogels for uncovering basic cellular biology; PEGSSDA that allows a researcher to dissolve hydrogel matrixes non-enzymatically; and polyethylene glycol tetra acrylate for modulating the physical properties of a hydrogel. In addition, it offers additives, such as PEPTITE-2000, a synthetic peptide containing the RGD cell attachment sequence; Vitronectin for use in cell culture applications; and Fibronectin for use in cell adhesion and attachment to extracellular matrix, as well as collagen based products. Further, the company provides vials, including HyStem, Heprasil, HyStem-HP, and Glycosil are thiol-modified hyaluronic acids; Gelin-S, a thiol-modified gelatin; Extralink, a polyethylene glycol diacrylate; and DG Water, a degassed and deionized water. Its products are also used in primary cell, cell line, cancer cell, tumor xenografts, angiogenesis, growth factor release, feeder free ESC culture, photolithography, gel contraction, invasion assay, and tubulogenesis applications. The company offers its products through distributors in North America, Europe, Japan, South Korea, Singapore, Thailand, and Malaysia. Glycosan BioSystems, Inc. was founded in 2006 and is based in Salt Lake City, Utah. As of March 21, 2011, Glycosan BioSystems, Inc. operates as a subsidiary of OrthoCyte Corporation
